178 related articles for article (PubMed ID: 21835906)
1. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.
Parkins MD; Rendall JC; Elborn JS
Chest; 2012 Feb; 141(2):485-493. PubMed ID: 21835906
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
3. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
6. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
7. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
[TBL] [Abstract][Full Text] [Related]
9. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
10. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
15. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
Sanders DB; Bittner RC; Rosenfeld M; Hoffman LR; Redding GJ; Goss CH
Am J Respir Crit Care Med; 2010 Sep; 182(5):627-32. PubMed ID: 20463179
[TBL] [Abstract][Full Text] [Related]
16. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa.
Béghin L; Michaud L; Loeuille GA; Wizla-Derambure N; Sayah H; Sardet A; Thumerelle C; Deschildre A; Turck D; Gottrand F
Pediatr Pulmonol; 2009 May; 44(5):464-71. PubMed ID: 19360849
[TBL] [Abstract][Full Text] [Related]
17. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
18. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Sequeiros IM; Jarad N
Chron Respir Dis; 2012 Feb; 9(1):9-16. PubMed ID: 22308550
[TBL] [Abstract][Full Text] [Related]
20. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure.
Juarez-Colunga E; Rosenfeld M; Zemanick ET; Wagner B
J Cyst Fibros; 2020 Jan; 19(1):114-118. PubMed ID: 30642785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
